Text Messages to Improve Quality of Life in PAH

The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

Recruiting N/A Interventional Study
Pulmonary Arterial Hypertension
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
100 (estimated)
Sponsor
Vanderbilt University Medical Center · Other
Who this trial is looking for

This trial is looking for adults with pulmonary arterial hypertension (PAH) to see if receiving smart texts helps improve their quality of life and exercise ability. Participants will either receive the text messages or usual care for 6 months.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am 18 years or older.
  • I have been diagnosed with pulmonary arterial hypertension.
  • I have a stable medication regimen for PAH for the past 3 months.
  • I have a forced vital capacity greater than 65% predicted.
  • I am in WHO functional class I-III.

You may not be able to join if

  • I cannot perform normal activities due to being wheelchair bound or bed bound.
  • I am currently pregnant.
  • I have been diagnosed with PAH due to a different cause than what is allowed.
  • I have functional class IV heart failure.
  • I have had more than 2 adjustments to my diuretic medications in the past 3 months.
  • My preferred form of activity is swimming, yoga, ice skating, or similar.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years. Increasing physical activity is highly efficacious in PAH, resulting in six-minute walk distance (6MWD) and HRQOL improvement that often exceeds the effect of medications. Prior activity stud…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adults aged 18 or older. * Diagnosed with idiopathic, heritable, or associated (connective tissue disease, drugs, or toxins) pulmonary arterial hypertension (PAH), or PAH due to simple congenital heart disease (i.e. atrial septal defect). * WHO functional class I-III * Stable …
Contacts

Alisha Lindsey, RT

615-322-3412

alisha.lindsey@vumc.org

CONTACT

Evan Brittain, MD

615-322-2318

evan.brittain@vumc.org

CONTACT